Printer Friendly

NEUTREXIN (TRIMETREXATE GLUCURONATE): AVAILABLE UNDER U.S. BIOSCIENCE TREATMENT IND

 WEST CONSHOHOCKEN, Pa., June 8 /PRNewswire/ -- U.S. Bioscience (AMEX: UBS) announced today that NeuTrexin is available to licensed physicians in the United States for patients with Pneumocystis carinii pneumonia (PCP) under the Treatment IND mechanism. The company has taken over sponsorship of the Treatment IND from the National Institutes of Health and has received permission from the U.S. Food and Drug Administration to expand access to NeuTrexin as an alternate therapy for patients with PCP who have relative contraindications to parenteral pentamidine as well as those who have demonstrated intolerance or have disease refractory to trimethoprim/sulfamethoxazole and pentamidine.
 "We are pleased to have the opportunity to provide expanded access to NeuTrexin with leucovorin protection for patients with PCP," said Edith Mitchell, M.D., director of clinical research for U.S. Bioscience. "PCP is an opportunistic infection that occurs in approximately 80 percent of AIDS patients. If not effectively treated, it is fatal. As many as 35-50 percent of these patients cannot tolerate or fail to respond to currently FDA-approved therapies. Clearly, alternative options are required. We believe that expanded access to NeuTrexin given with leucovorin protection provides a viable alternative therapy."
 "NeuTrexin," Mitchell explained, "is a lipophilic antifolate which, unlike methotrexate, can penetrate both normal cells and the cells of organisms such as Pneumocystis carinii. Leucovorin (folinic acid), a reduced folate, protects normal organs from the toxic effects of NeuTrexin. Leucovorin enters normal cells via the reduced folate transport carrier located in the membrane of healthy cells, but cannot enter Pneumocystis carinii which do not possess this membrane transport mechanism. Therefore, leucovorin can be used to protect healthy cells from the effect of NeuTrexin without affecting its cytotoxicity against Pneumocystis carinii."
 To date, over 500 U.S. physicians have treated patients with PCP with NeuTrexin and leucovorin protection under the Treatment IND mechanism. Physicians may enter eligible patients onto the Treatment IND protocol and obtain NeuTrexin and leucovorin by calling 800-537-9978. Someone is available to respond to your call 24 hours a day, seven days a week.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases such as AIDS. The company's portfolio includes a broad spectrum of compounds, including two products for which new drug applications have been filed and two others in the late stages of development. One compound, altretamine, is marketed under the name Hexalen in the United States for the treatment of ovarian cancer.
 /delval/
 -0- 6/8/93
 /NOTE: For medical inquiries, please call Edith Mitchell at the number below. Please call Robert I. Kriebel for corporate inquiries.
 NeuTrexin is a trademark. Hexalen is a registered trademark./
 /CONTACT: Edith Mitchell, M.D., director, clinical research, 215-832-4525, or Robert I. Kriebel, senior vice president, finance and administration, 215-832-4503, both of U.S. Bioscience/
 (UBS)


CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU: PDT

IH-DC -- DC013 -- 6486 06/08/93 11:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:504
Previous Article:INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES SIGNING OF SUDS HIV 1+2 SALES CONTRACT IN SCANDINAVIA
Next Article:BIG THREE PLAN COOPERATION ON MATERIALS RESEARCH
Topics:


Related Articles
U.S. BIOSCIENCE REPORTS RESULTS FOR FOURTH QUARTER AND YEAR
U.S. BIOSCIENCE GETS CLEARANCE FOR NEUTREXIN; ADDITIONAL INFORMATION REQUESTED ON ETHYOL
TRIMETREXATE APPROVED FOR TREATMENT OF PCP, SAYS FDA
U.S. BIOSCIENCE ANNOUNCES FOURTH QUARTER RESULTS, INCLUDING $.26 PER SHARE ONE-TIME CHARGE
MACMASTER, FORMER MERCK EXECUTIVE, NAMED TO U.S. BIOSCIENCE BOARD
U.S. BIOSCIENCE ANNOUNCES FIRST QUARTER RESULTS
U.S. BIOSCIENCE APPOINTS CHRISTINE SMITH DIRECTOR OF REGULATORY AFFAIRS
U.S. BIOSCIENCE ANNOUNCES SECOND QUARTER RESULTS
ODAC WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL; U.S. BIOSCIENCE, INC. TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF ETHYOL
MedImmune, Inc. to Acquire U.S. Bioscience, Inc. -Acquisition Provides Immediate Products and Infrastructure in Oncology-.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters